BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia

Dysregulation of the BCL-2 family is implicated in protecting chronic myeloid leukemia (CML) cells from intracellular damage and BCR::ABL1-inhibition with tyrosine kinase inhibitors (TKIs) and may be a viable therapeutic target in blast phase (BP-)CML, for which treatment options are limited. BH3 mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Parry, Narissa, Busch, Caroline, Aßmann, Victoria, Cassels, Jennifer, Hair, Alan, Helgason, G. Vignir, Wheadon, Helen, Copland, Mhairi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666353/
https://www.ncbi.nlm.nih.gov/pubmed/36379918
http://dx.doi.org/10.1038/s41420-022-01211-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666353/
https://www.ncbi.nlm.nih.gov/pubmed/36379918
http://dx.doi.org/10.1038/s41420-022-01211-1

Ejemplares similares